



National Comprehensive
Cancer Network®

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Dermatofibrosarcoma Protuberans

Version 1.2024 — November 9, 2023

NCCN.org

Continue



***Chrysalyn D. Schmults, MD, MS/Chair** ω \neq \uparrow
Dana-Farber/Brigham and Women's
Cancer Center | Mass General Cancer Center

Rachel Blitzblau, MD, PhD/Vice Chair \S
Duke Cancer Institute

Sumaira Z. Aasi, MD ω
Stanford Cancer Institute

***Murad Alam, MD, MBA, MSCI** ω \uparrow ζ
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

Arya Amini, MD \S
City of Hope National Medical Center

Kristin Bibee, MD, PhD ω
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

Jeremy Bordeaux, MD, MPH ω
Case Comprehensive Cancer Center/
University Hospitals Seidman Cancer Center
and Cleveland Clinic Taussig Cancer Institute

Pei-Ling Chen, MD, PhD \neq
Moffitt Cancer Center

Carlo M. Contreras, MD \uparrow
The Ohio State University Comprehensive
Cancer Center - James Cancer Hospital
and Solove Research Institute

Dominick DiMaio, MD \neq
Fred & Pamela Buffett Cancer Center

Jessica M. Donigan, MD ω \uparrow
Huntsman Cancer Institute
at the University of Utah

Jeffrey M. Farma, MD \uparrow
Fox Chase Cancer Center

Karthik Ghosh, MD \neq
Mayo Clinic Comprehensive Cancer Center

Kelly Harms, MD, PhD ω
University of Michigan Rogel Cancer Center

Alan L. Ho, MD, PhD \dagger
Memorial Sloan Kettering Cancer Center

John Nicholas Lukens, MD \S
Abramson Cancer Center
at the University of Pennsylvania

Susan Manber \neq
Publicis Health

Lawrence Mark, MD, PhD ω
Indiana University Melvin and Bren Simon
Comprehensive Cancer Center

Theresa Medina, MD \dagger
University of Colorado Cancer Center

Kishwer S. Nehal, MD ω
Memorial Sloan Kettering Cancer Center

Paul Nghiem, MD, PhD ω
Fred Hutchinson Cancer Center

Kelly Olino, MD \uparrow
Yale Cancer Center/Smilow Cancer Hospital

Soo Park, MD \dagger
UC San Diego Moores Cancer Center

Tejesh Patel, MD ω
The University of Tennessee Health Science Center

Igor Puzanov, MD, MSCI \ddagger
Roswell Park Comprehensive Cancer Center

Jason Rich, MD ζ
Siteman Cancer Center at Barnes-Jewish Hospital
and Washington University School of Medicine

Aleksandar Sekulic, MD, PhD ω
Mayo Clinic Comprehensive Cancer Center

Ashok R. Shaha, MD \uparrow ζ
Memorial Sloan Kettering Cancer Center

Divya Srivastava, MD ω
UT Southwestern Simmons
Comprehensive Cancer Center

Valencia Thomas, MD ω
The University of Texas
MD Anderson Cancer Center

Courtney Tomblinson, MD ϕ
Vanderbilt-Ingram Cancer Center

Puja Venkat, MD \S
UCLA Jonsson Comprehensive Cancer Center

Yaohui Gloria Xu, MD, PhD ω \ddagger
University of Wisconsin
Carbone Cancer Center

Siegrid Yu, MD ω
UCSF Helen Diller Family Comprehensive Cancer Center

Mehran Yusuf, MD \S
O'Neal Comprehensive Cancer Center at UAB

NCCN

Sara Espinosa, PhD
Beth McCullough, RN, BS

ω Dermatology	\neq Pathology/ Dermatopathology
ϕ Diagnostic/Interventional radiology	\neq Patient advocacy
\ddagger Hematology/Hematology oncology	\ddagger Reconstructive surgery
\neq Internal medicine	\S Radiotherapy/Radiation oncology
\dagger Medical oncology	\uparrow Surgery/Surgical oncology
ζ Otolaryngology	* Discussion Section Writing Committee



[NCCN Dermatofibrosarcoma Protuberans Panel Members](#)
[Summary of the Guidelines Updates](#)

[Clinical Presentation and Workup \(DFSP-1\)](#)
[Treatment and Follow-up \(DFSP-2\)](#)
[Therapy for Recurrence/Metastasis \(DFSP-3\)](#)

[Principles of Pathology \(DFSP-A\)](#)
[Principles of Surgery \(DFSP-B\)](#)
[Principles of Radiation Therapy \(DFSP-C\)](#)

[Abbreviations \(ABBR-1\)](#)

Clinical Trials: NCCN believes that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Find an NCCN Member Institution:
<https://www.nccn.org/home/member-institutions>.

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise indicated.

[See NCCN Categories of Evidence and Consensus.](#)

NCCN Categories of Preference: All recommendations are considered appropriate.

[See NCCN Categories of Preference.](#)

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2023.



Terminologies in all NCCN Guidelines are being actively modified to advance the goals of equity, inclusion, and representation.

Updates in Version 1.2024 of the NCCN Guidelines for Dermatofibrosarcoma Protuberans from Version 1.2023 include:

[DFSP-1](#)

- Preliminary Workup, third bullet removed: Consider preoperative MRI with contrast for treatment planning if extensive subcutaneous extension is suspected.
- Additional Workup, new bullet added: Consider preoperative MRI with contrast for treatment planning if extensive subcutaneous extension is suspected.
- Footnote removed: For more information, see American Academy of Dermatology Association.

[DFSP-2](#)

- Treatment, bullet revised: *For unresectable/borderline resectable disease, Consider tumor mutation analysis and neoadjuvant imatinib for unresectable/borderline resectable disease.*
- Adjuvant Treatment, bottom pathway following Positive margins revised: Multidisciplinary consultation for consideration of radiation therapy (RT) or other therapy.
- Therapy for Recurrence/Metastasis moved to new page DFSP-3.

[DFSP-3](#)

- New page for Therapy for Recurrence/Metastasis information that was previously on DFSP-2.
- Footnote j revised: *Confirmation of tumor mutation with FISH for the translocation of PDGRF.* Navarrete-Dechent C, et al. JAMA Dermatol 2019;155:361-369.

[DFSP-B](#)

- Header revised: Principles of ~~Excision~~ Surgery.
- New reference added: Farma JM, Ammori JB, Zager JS, et al. Dermatofibrosarcoma protuberans: how wide should we resect? Ann Surg Oncol 2010;17:2112-2118.



NCCN Guidelines Version 1.2024


Dermatofibrosarcoma Protuberans

CLINICAL PRESENTATION

PRELIMINARY WORKUP

DIAGNOSIS

ADDITIONAL WORKUP



^a This tumor is frequently misdiagnosed due to inadequate tissue sampling/superficial biopsy. Punch, incisional, or core biopsy, preferably including the deeper subcutaneous layer, is strongly recommended for sufficient tissue sampling and accurate pathologic assessment. If biopsy is indeterminate or clinical suspicion remains, rebiopsy is recommended. Wide undermining is discouraged due to the difficulty of interpreting subsequent re-excisions pathologically.


^b [Principles of Pathology \(DFSP-A\)](#).

^c If areas of transformation to fibrosarcoma or other sarcoma subtypes are identified, multidisciplinary consultation for consideration of further treatment and surveillance is recommended. FS-DFSP is associated with a metastasis risk of 15%–20%. See [NCCN Guidelines for Soft Tissue Sarcoma](#) for multimodal therapy and surveillance considerations including CT of draining nodal basin and chest.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

TREATMENT



^c If areas of transformation to fibrosarcoma or other sarcoma subtypes are identified, multidisciplinary consultation for consideration of further treatment and surveillance is recommended. FS-DFSP is associated with a metastasis risk of 15%–20%. See [NCCN Guidelines for Soft Tissue Sarcoma](#) for multimodal therapy and surveillance considerations including CT of draining nodal basin and chest.

^d The most commonly used form of PDEMA is Mohs. See [NCCN Guidelines for Squamous Cell Skin Cancer - Principles of PDEMA Technique](#). When anatomic structures at the deep margin (eg, major vessels, nerves, bone) preclude complete histologic evaluation of the marginal surface via Mohs or other forms of PDEMA, Mohs or other forms of PDEMA should be used to evaluate as much of the marginal surface as feasible. Treatment considerations for non-visualized areas may be the subject of multidisciplinary discussion.

^e If PDEMA is unavailable, consider wide excision. Wide undermining is discouraged prior to confirmation of clear margins due to the difficulty of interpreting subsequent re-excised margins, and the risk of concealing residual tumor below mobilized tissue. See [Principles of Surgery \(DFSP-B\)](#).

^f Consider neoadjuvant imatinib for patients in whom resection with negative margins may result in unacceptable functional or cosmetic outcomes. Ugurel S, et al. Clin Cancer Res 2014;20:499-510.


^g [Principles of Radiation Therapy \(DFSP-C\)](#).

^h When Mohs or other forms of PDEMA are utilized and margins are negative, RT is not recommended. When Mohs or other forms of PDEMA are not utilized, consider RT if margins are considered narrow by the treating physicians. RT can be considered for treatment of positive margins if not given previously and further resection is not feasible.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



THERAPY FOR RECURRENCE/METASTASIS



^d The most commonly used form of PDEMA is Mohs. See [NCCN Guidelines for Squamous Cell Skin Cancer - Principles of PDEMA Technique](#). When anatomic structures at the deep margin (eg, major vessels, nerves, bone) preclude complete histologic evaluation of the marginal surface via Mohs or other forms of PDEMA, Mohs or other forms of PDEMA should be used to evaluate as much of the marginal surface as feasible. Treatment considerations for non-visualized areas may be the subject of multidisciplinary discussion.

^e If PDEMA is unavailable, consider wide excision. Wide undermining is discouraged prior to confirmation of clear margins due to the difficulty of interpreting subsequent re-excised margins, and the risk of concealing residual tumor below mobilized tissue. See [Principles of Surgery \(DFSP-B\)](#).

^g [Principles of Radiation Therapy \(DFSP-C\)](#).

^h When Mohs or other forms of PDEMA are utilized and margins are negative, RT is not recommended. When Mohs or other forms of PDEMA are not utilized, consider RT if margins are considered narrow by the treating physicians. RT can be considered for treatment of positive margins if not given previously and further resection is not feasible.

ⁱ Confirm tumor mutation with fluorescence in situ hybridization (FISH) for the translocation of *PDGRF*. Navarrete-Dechent C, et al. JAMA Dermatol 2019;155:361-369.

^j [NCCN Guidelines for Soft Tissue Sarcoma \(Synchronous STAGE IV \[EXTSARC-5\]\)](#).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



PRINCIPLES OF PATHOLOGY¹

- Evaluation by a qualified physician with specific expertise in sarcoma/soft tissue pathology or dermatopathology is preferred (if available).
- The spindled cells arranged in a storiform or fascicular pattern are typically bland with minimal cytologic atypia.
- Immunohistochemistry for CD34 is mostly positive, and factor XIIIa negative.
- FS-DFSP² is characterized by transition from storiform to a herringbone pattern, with a higher degree of cellularity, cytologic atypia, mitotic activity (>5/10 high-power fields [HPFs]), and frequent loss of CD34 immunostaining. When CD34 is negative, other markers such as S100 should also be negative to rule out other spindle cell tumors.
- For equivocal lesions, consider fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), or conventional cytogenetics to detect t(17;22)(q22;q13), which is a hallmark of DFSP. Fusion of the collagen type I alpha 1 gene (*COL1A1*) at 17q22, with the platelet-derived growth factor Beta gene (*PDGFβ*) at 22q13, form the oncogenic chimeric fusion gene *COL1A1::PDGFβ*.
- Margin control during excision (see [Principles of Surgery \[DFSP-B\]](#)) may occasionally be aided by H&E sections supplemented by CD34 immunohistochemistry.

¹ Currently, no American Joint Committee on Cancer (AJCC) or College of American Pathologists (CAP) synoptic reporting is defined.

² If areas of transformation to fibrosarcoma or other sarcoma subtypes are identified, multidisciplinary consultation for consideration of further treatment and surveillance is recommended. FS-DFSP is associated with a metastasis risk of 15%–20%. The patient should be referred to a center with expertise in management of soft tissue sarcomas. See [NCCN Guidelines for Soft Tissue Sarcoma](#) for multimodal therapy and surveillance considerations including CT of draining nodal basin and chest.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



PRINCIPLES OF SURGERY

Goal:

- **Every effort should be made to achieve clear surgical margins. Complete histologic surgical margin examination to include the entire excised peripheral and deep margin is recommended, whenever possible. Tumor characteristics include long, irregular, subclinical extensions. Debulking specimens from all excisions should be examined to identify FS-DFSP since this is associated with metastatic potential.**

Surgical Approach: Mohs or Other Forms of PDEMA

- [NCCN Guidelines for Squamous Cell Skin Cancer - Principles of PDEMA Technique](#)
- **If Mohs or other forms of PDEMA are unavailable, consider wide excision.¹**
 - ▶ **Reconstruction should be delayed until clear margins have been verified to avoid the risk of translocating the tumor within the resection bed, thus making further margin assessments inaccurate.**

¹ Farma JM, Ammori JB, Zager JS, et al. Dermatofibrosarcoma protuberans: how wide should we resect? *Ann Surg Oncol* 2010;17:2112-2118.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



PRINCIPLES OF RADIATION THERAPY

General Treatment Information

• Adjuvant RT:

▶ Positive Margins/Gross Disease

- ◊ 50–60 Gy for indeterminate or positive margins, and up to 66 Gy for positive margins or gross tumor (2-Gy fractions per day).
- ◊ Fields to extend widely beyond surgical margins (eg, 3–5 cm) when clinically feasible.

▶ Negative Margins

- ◊ When Mohs or other forms of PDEMA are utilized, RT is not recommended.
- ◊ When Mohs or other forms of PDEMA are not utilized, consider RT if margins are <1 cm.

• Recurrence/Metastasis:

- ▶ RT if not given previously and further resection is not feasible; 50–60 Gy for indeterminate or positive margins, and up to 66 Gy for positive margins or gross tumor (2-Gy fractions per day).
- ▶ Fields to extend widely beyond surgical margins (eg, 3–5 cm) when clinically feasible.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



ABBREVIATIONS

CAP	College of American Pathologists
DFSP	dermatofibrosarcoma protuberans
FISH	fluorescence in situ hybridization
FS-DFSP	fibrosarcomatous transformation of DFSP
H&E	hematoxylin and eosin
H&P	history and physical
HPFs	high-power fields
PCR	polymerase chain reaction
PDEMA	peripheral and deep en face margin assessment



NCCN Guidelines Version 1.2024

Dermatofibrosarcoma Protuberans

NCCN Categories of Evidence and Consensus	
Category 1	Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2A	Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2B	Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
Category 3	Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise indicated.

NCCN Categories of Preference	
Preferred intervention	Interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability.
Other recommended intervention	Other interventions that may be somewhat less efficacious, more toxic, or based on less mature data; or significantly less affordable for similar outcomes.
Useful in certain circumstances	Other interventions that may be used for selected patient populations (defined with recommendation).

All recommendations are considered appropriate.




NCCN Guidelines Version 1.2024 Dermatofibrosarcoma Protuberans

Discussion

This discussion corresponds to the NCCN Guidelines for Dermatofibrosarcoma Protuberans. Last updated: January 31st, 2022.

Table of Contents

Overview	MS-2
Literature Search Criteria and Guidelines Update Methodology	MS-2
Evaluation	MS-2
Treatment.....	MS-3
Follow-up	MS-4
References.....	MS-2





Overview

Dermatofibrosarcoma protuberans (DFSP) is an uncommon, low-grade sarcoma of fibroblast origin with an incidence rate of 4.1 to 4.5 cases per million persons per year in the United States.¹⁻⁴ A predilection for occurring in African Americans has been reported in one study.³ Initial misdiagnosis, prolonged time to accurate diagnosis, and large tumor size at the time of diagnosis are common. However, it rarely metastasizes.⁵ When metastasis occurs, it is typically in the lung, bone, or regional lymph nodes. Three-dimensional reconstruction of DFSP⁶ has revealed tumors with highly irregular shapes and frequent finger-like extensions.⁷ As a result, incomplete removal and subsequent recurrence are common without attention to full assessment of the peripheral and deep margin. The local recurrence rate for wide local excision (WLE) of DFSP in studies ranges from 10% to 60%, whereas the rate of development of regional or distant metastatic disease is only 1% and 4% to 7.4%, respectively.^{8,9}

Literature Search Criteria and Guidelines Update Methodology

Prior to the update of this version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Dermatofibrosarcoma Protuberans, an electronic search of the PubMed database was performed to obtain key literature using the following search term: dermatofibrosarcoma protuberans. The PubMed database was chosen as it remains the most widely used resource for medical literature and indexes peer-reviewed biomedical literature.¹⁰

The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial; Guideline; Meta-Analysis; Randomized Controlled Trial; Systematic Reviews; and Validation Studies.

The data from key PubMed articles as well as articles from additional sources deemed as relevant to these guidelines and discussed by the panel have been included in this version of the Discussion section (eg, e-publications ahead of print, meeting abstracts). Recommendations for which high-level evidence is lacking are based on the panel's review of lower-level evidence and expert opinion.

The complete details of the Development and Update of the NCCN Guidelines are available at www.NCCN.org.

Evaluation

Histologically, DFSP typically presents as a storiform or fascicular proliferation of bland spindled cells that extends from the dermis into the subcutis.^{11,12} Virtually all cases are CD34-positive and factor XIIIa-negative with rare exceptions.^{13,14} Currently, no synoptic reporting is recommended. Workup for DFSP consists of history and physical (H&P) examination, complete skin examination, and biopsy. It should be noted that this tumor is frequently misdiagnosed due to inadequate tissue sampling resulting from shallow biopsy. As the superficial aspect of a DFSP may not be distinct from benign lesions, a punch or incisional biopsy that samples the subcutaneous layer, is strongly recommended. If a biopsy is indeterminate or clinical suspicion remains, rebiopsy is recommended.

In most cases, examination of hematoxylin and eosin-stained specimens by light microscopy results in an unequivocal diagnosis. However, differentiation of DFSP from dermatofibroma can be difficult at times. In such instances, staining with CD34,^{14,15} factor XIIIa,^{13,16} stromelysins 3,¹⁷ and other immunomarkers such as nestin, apolipoprotein D, and cathepsin K,¹⁸⁻²⁰ might be useful. The NCCN Panel recommends that appropriate and confirmatory immunostaining be performed in all cases of suspected DFSP.



NCCN Guidelines Version 1.2024

Dermatofibrosarcoma Protuberans

It is unclear whether the histologic features of a high mitotic rate or evidence of fibrosarcomatous (FS) change (FS-DFSP) have prognostic significance in DFSP.^{21,22} Studies in the biomedical literature both support the connection between FS-DFSP and an increased risk of local recurrence, lower time to recurrence, and increased risk of metastasis,²³⁻³¹ and refute^{32,33} this notion. A systematic review of 1422 patients with DFSP and 225 with DFSP-FS reported risks of local recurrence (29.8% vs. 13.7%), metastasis (14.4% vs. 1.1%), and death (14.7% vs. 0.8%) from the disease to be significantly higher in DFSP-FS versus DFSP.³⁴ The NCCN Panel recommends that FS change and other high-risk features such as deep lesions and high grade be noted in all pathology reports assessing this tumor. If FS transformation is found, multidisciplinary consultation for consideration of further treatment and surveillance is recommended. Clinicians should consult the [NCCN Guidelines for Soft Tissue Sarcoma](#). Overall, as decisions about diagnosis and resection may be complex, multidisciplinary consultation at a center with specialized expertise should be strongly considered, especially for large or recurrent DFSP as it may optimize clinical and reconstructive outcomes.^{35,36}

Treatment

Initial treatment of DFSP is surgical. Because of its proclivity for irregular and frequently deep subclinical extensions, every effort should be made to completely remove this tumor at the time of initial therapy. Excision with Mohs micrographic surgery (Mohs) or other forms of peripheral and deep en face margin assessment (PDEMA) is recommended over WLE. En face sectioning is preferred to prevent missing small foci of tumor. The most commonly used form of PDEMA is Mohs (Refer to [NCCN Guidelines for Squamous Cell Skin Cancer – Principles of PDEMA Technique](#)). When anatomic structures at the deep margin (eg, major vessels, nerves, bone) preclude complete histologic evaluation of the marginal surface via Mohs or other forms of

PDEMA, Mohs and other forms of PDEMA should be used to evaluate as much of the marginal surface as feasible. A combination of PDEMA and WLE for the deep margin has been reported in the literature.³⁶ Treatment considerations for non-visualized areas may be the subject of multidisciplinary discussion. If PDEMA is unavailable, WLE can be considered. Wide undermining is discouraged prior to confirmation of clear margins due to the difficulty of interpreting subsequent re-excised margins, and the risk of concealing residual tumor below mobilized tissue. If initial surgery yields positive margins, re-resection is recommended whenever possible, with the goal of achieving clear margins.

Mohs or modified Mohs surgery, and traditional WLE with wider margins, which has been associated with higher tumor clearance and lower rates of recurrence,³⁷⁻³⁹ are all methods to achieve complete histologic assessment. Studies examining outcomes of both Mohs and WLE have consistently reported lower recurrence rates for the former (0%–6.6% vs. 1.7%–30.8%) (Table 1).⁴⁰⁻⁴⁹ The weight of the evidence supports the NCCN Panel's preference for Mohs using either frozen or permanent sections.⁵⁰⁻⁵³ A large retrospective series of 204 patients with DFSP showed a very low local recurrence rate (1%) using WLE with total peripheral margin pathologic evaluation, underscoring the importance of meticulous pathologic margin evaluation with any surgical technique.⁵⁴ This notion was also supported by more recent studies.^{55,56} It is recommended that any reconstruction involving extensive undermining be avoided. Tissue rearrangement, if necessary, should be delayed until negative histologic margins are verified to prevent displacing a potentially positive margin or hampering interpretation of re-excisions. If there is concern that the surgical margins are not clear when Mohs or PDEMA is not available, split-thickness skin grafting should be considered to monitor for recurrence.



NCCN Guidelines Version 1.2024

Dermatofibrosarcoma Protuberans

Radiation therapy (RT) has occasionally been used as a primary therapeutic modality for DFSP,⁵⁷⁻⁵⁹ but it is most beneficial as adjuvant therapy after surgery.⁵⁷⁻⁶⁴ In a single-institution retrospective review of 53 patients treated with surgery and preoperative or postoperative RT, local control was 93% and actuarial overall survival was 98% at 10 years.³³ Another small patient series reported that 86% of patients treated with postoperative RT remained disease-free at a median follow-up of 10.5 years.⁶³ In a systematic review and meta-analysis of adjuvant RT for DFSP after WLE, the overall recurrence rate was reported to be 11.74%. Patients with positive/close margins had a recurrence rate of 14.23% whereas those with negative margins had no recurrence.⁶⁵ The NCCN Panel recommends that if a negative margin is achieved, no adjuvant treatment is necessary. When Mohs or other forms of PDEMA are used, RT is not recommended. When Mohs or other forms of PDEMA are not used, RT can be considered if margins are less than 1 cm. RT can be considered for the treatment of positive margins if not given previously and further resection is not feasible.

DFSP can be treated by targeted PDGF receptors. DFSP is characterized by a translocation between chromosomes 17 and 22 [t(17;22)(q22;q13)] resulting in the overexpression of platelet-derived growth factor receptor β (PDGFR β).⁶⁶⁻⁶⁸ These findings suggest that targeting PDGF receptors may be an effective treatment for DFSP. In published results, imatinib mesylate, a protein tyrosine kinase inhibitor, has shown clinical activity against DFSP,⁶⁹⁻⁷⁴ which has led to its approval by the U.S. Food and Drug Administration (FDA) for the treatment of unresectable, recurrent, and/or metastatic DFSP in adult patients. It is still unclear whether or not and the extent to which the COL1A1-PDGFB fusion gene dictates imatinib response.⁷⁰ In a recent systematic review that included patients receiving imatinib as monotherapy, adjuvant, or neoadjuvant therapy, complete response,

partial response, stable disease, and progressive disease were reported in 5.2%, 55.2%, 27.6%, and 9.2% of patients, respectively.⁷⁰ The panel recommends neoadjuvant imatinib for patients in whom resection with negative margins may result in unacceptable functional or cosmetic outcomes. In the neoadjuvant setting, complete response, partial response, stable disease, and progressive disease rates were reported to be 7.1%, 50%, 35.7%, and 7.1%, respectively.⁷¹

Follow-up

Given the historically high local recurrence rates for DFSP, ongoing clinical follow-up with focus on the primary site every 6 to 12 months is indicated, with re-biopsy of any suspicious regions. Although metastatic disease is rare, a guided H&P and patient education about regular self-examination are recommended. For patients with high-risk features or who have undergone extensive surgery, additional imaging studies may be useful in detecting recurrence. MRI with contrast may be helpful to detect early recurrence in patients with high-risk lesions or delineate tumor extent when physical examination is insufficient or unreliable.

Recurrent tumors should be resected whenever possible. Adjuvant RT may be considered after surgery. For patients who are not surgical candidates, RT alone is an option if not given previously. Imatinib mesylate should be considered in cases where the disease is unresectable following multiple resections, or if unacceptable functional or cosmetic outcomes will occur with further resection.

In the rare event of metastatic disease, multidisciplinary consultation is recommended to coordinate treatment (Refer to [NCCN Guidelines for Soft Tissue Sarcoma](#)).



Table 1. Summary of Retrospective Reviews, Systematic Reviews, and Meta-Analyses Investigating Locoregional Recurrence Rates by Mohs Micrographic Surgery and Wide Local Excision for DFSP

<i>Author - Year</i>	<i>Study Type</i>	<i>Number of Tumors</i>	<i>Surgical Technique (n)</i>	<i>Locoregional Recurrence Rate (%)</i>	<i>Notes</i>
Gloster 1996 ⁴⁰	Review (retrospective series)	15	Mohs	6.6%	Median follow-up 40 months
		39	WLE	10%	Median follow-up 36 months
Gloster 1996 ⁴⁰	Review (literature search)	64	Mohs	1.6%	Total across 11 studies
		489	WLE	20%	Total across 15 studies
Dubay 2004 ⁴¹	Retrospective review	63	Mohs (11) WLE (43) Combination (9)	0%	Median follow-up 52.8 months
Paradisi 2008 ⁴⁵	Retrospective review (retrospective series)	41	Mohs	0%	Mean follow-up 5.4 years
		38	WLE	13.2%	Mean follow-up 4.8 years
	Retrospective review (literature search)	463	Mohs	1.3%	Total across 30 studies
		1394	WLE	20.7%	Total across 31 studies
Meguerditchian 2010 ⁴²	Retrospective review	20	Mohs	0%	Median follow-up 40.4 months
		28	WLE	3.6%	Median follow-up 49.9 months
Foroozan 2012 ⁴³	Systematic review (non-randomized comparative studies)	90	Mohs	1.1%	Total across 4 studies
		174	WLE	6.3%	Total across 4 studies
Bogucki 2012 ⁴⁴	Literature review	444	Mohs	1.1%	Total across 20 studies
		1443	WLE	7.3%	Total across 20 studies
Lowe 2017 ⁴⁶	Retrospective review	67	Mohs	3.0%	Mean follow-up 4.8 years
		91	WLE	30.8%	Mean follow-up 5.7 years
Veronese 2017 ⁴⁷	Review (retrospective series)	73	Mohs Tubingen	5.5%	Median follow-up 9 years
		62	WLE	8.1%	Median follow-up 4.7 years
	Review (literature search)	424	Mohs	0.94%	Total across 16 studies
		82	Mohs Tubingen	0%	Total across 3 studies
		1465	WLE	14.9%	Total across 30 studies
Malan 2019 ⁴⁸	Meta-analysis	298	Mohs	2.7%	Median follow-up 5.32 years
		389	WLE	9.10%	Median follow-up 5.32 years
Durack 2021 ⁴⁹	Retrospective review	97	Mohs	0%	Median follow-up 25.5 months
		362	WLE	1.7%	Median follow-up 25.5 months

WLE, wide local excision

**References**

1. Criscione VD, Weinstock MA. Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. *J Am Acad Dermatol* 2007;56:968-973. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17141362>.
2. Rouhani P, Fletcher CD, Devesa SS, Toro JR. Cutaneous soft tissue sarcoma incidence patterns in the U.S. : an analysis of 12,114 cases. *Cancer* 2008;113:616-627. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18618615>.
3. Kreicher KL, Kurlander DE, Gittleman HR, et al. Incidence and Survival of Primary Dermatofibrosarcoma Protuberans in the United States. *Dermatol Surg* 2016;42 Suppl 1:S24-31. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26730971>.
4. Criscito MC, Martires KJ, Stein JA. Prognostic Factors, Treatment, and Survival in Dermatofibrosarcoma Protuberans. *JAMA Dermatol* 2016;152:1365-1371. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27262160>.
5. Martin L, Piette F, Blanc P, et al. Clinical variants of the preprotuberant stage of dermatofibrosarcoma protuberans. *Br J Dermatol* 2005;153:932-936. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16225602>.
6. Haycox CL, Odland PB, Olbricht SM, Casey B. Dermatofibrosarcoma protuberans (DFSP): growth characteristics based on tumor modeling and a review of cases treated with Mohs micrographic surgery. *Ann Plast Surg* 1997;38:246-251. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9088462>.
7. Ratner D, Thomas CO, Johnson TM, et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. *J Am Acad Dermatol* 1997;37:600-613. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9344201>.
8. Hayakawa K, Matsumoto S, Ae K, et al. Risk factors for distant metastasis of dermatofibrosarcoma protuberans. *J Orthop Traumatol* 2016. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27289468>.
9. Vidimos AT, Helm TN, Papay FA. Dermatofibrosarcoma protuberans. In: *Cutaneous Oncology: Pathophysiology, Diagnosis, and Management*. Malden, MA: Blackwell Scientific; 1998.
10. PubMed Overview. Available at: <https://pubmed.ncbi.nlm.nih.gov/about/>. Accessed November 15th, 2021.
11. Mentzel T, Pedeutour F, Lazar A, Coindre JM, eds. Dermatofibrosarcoma Protuberans in WHO Classification of Tumors of Soft Tissue and Bone. In: Fletcher CD, Bridge JA, Hogendoorn PCW, Mertens F, eds (ed 4): IARC Press; 2013.
12. Connective Tissue Tumors. In: Calonje E, Brenn T, Lazar A, McKee PH, eds. *McKee's Pathology of the Skin with Clinical Correlations* (ed 4): Elsevier Saunders; 2012:1630-1635.
13. Abenzoza P, Lillemoe T. CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans. *Am J Dermatopathol* 1993;15:429-434. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7694515>.
14. Aiba S, Tabata N, Ishii H, et al. Dermatofibrosarcoma protuberans is a unique fibrohistiocytic tumour expressing CD34. *Br J Dermatol* 1992;127:79-84. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1382538>.
15. Kutzner H. Expression of the human progenitor cell antigen CD34 (HPCA-1) distinguishes dermatofibrosarcoma protuberans from fibrous histiocytoma in formalin-fixed, paraffin-embedded tissue. *J Am Acad Dermatol* 1993;28:613-617. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7681857>.
16. Goldblum JR, Tuthill RJ. CD34 and factor-XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma. *Am J*



Dermatopathol 1997;19:147-153. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/9129699>.

17. Cribier B, Noacco G, Peltre B, Grosshans E. Stromelysin 3 expression: a useful marker for the differential diagnosis dermatofibroma versus dermatofibrosarcoma protuberans. *J Am Acad Dermatol* 2002;46:408-413. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/11862177>.

18. Sellheyer K, Nelson P, Krahl D. Dermatofibrosarcoma protuberans: a tumour of nestin-positive cutaneous mesenchymal stem cells? *Br J Dermatol* 2009;161:1317-1322. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/19659472>.

19. Lisovsky M, Hoang MP, Dresser KA, et al. Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans. *Mod Pathol* 2008;21:31-38. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/17885669>.

20. Yan X, Takahara M, Xie L, et al. Cathepsin K expression: a useful marker for the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans. *Histopathology* 2010;57:486-488. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/20727023>.

21. Connelly JH, Evans HL. Dermatofibrosarcoma protuberans. A clinicopathologic review with emphasis on fibrosarcomatous areas. *Am J Surg Pathol* 1992;16:921-925. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/1415902>.

22. Szollosi Z, Nemes Z. Transformed dermatofibrosarcoma protuberans: a clinicopathological study of eight cases. *J Clin Pathol* 2005;58:751-756. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/15976346>.

23. Mentzel T, Beham A, Katenkamp D, et al. Fibrosarcomatous ("high-grade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis

on prognostic significance. *Am J Surg Pathol* 1998;22:576-587. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/9591728>.

24. Bowne WB, Antonescu CR, Leung DH, et al. Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution. *Cancer* 2000;88:2711-2720. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/10870053>.

25. Abbott JJ, Oliveira AM, Nascimento AG. The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans. *Am J Surg Pathol* 2006;30:436-443. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/16625088>.

26. Ding J, Hashimoto H, Enjoji M. Dermatofibrosarcoma protuberans with fibrosarcomatous areas. A clinicopathologic study of nine cases and a comparison with allied tumors. *Cancer* 1989;64:721-729. Available at:
<https://pubmed.ncbi.nlm.nih.gov/2545326/>.

27. Hoesly PM, Lowe GC, Lohse CM, et al. Prognostic impact of fibrosarcomatous transformation in dermatofibrosarcoma protuberans: a cohort study. *J Am Acad Dermatol* 2015;72:419-425. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/25582537>.

28. Lyu A, Wang Q. Dermatofibrosarcoma protuberans: A clinical analysis. *Oncol Lett* 2018;16:1855-1862. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/30008876>.

29. Erdem O, Wyatt AJ, Lin E, et al. Dermatofibrosarcoma protuberans treated with wide local excision and followed at a cancer hospital: prognostic significance of clinicopathologic variables. *Am J Dermatopathol* 2012;34:24-34. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/21785324>.

30. Jing C, Zhang H, Zhang X, Yu S. Dermatofibrosarcoma Protuberans: A Clinicopathologic and Therapeutic Analysis of 254 Cases at a Single Institution. *Dermatol Surg* 2021;47:e26-e30. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/32769521>.



31. Li Y, Wang C, Xiang B, et al. Clinical Features, Pathological Findings and Treatment of Recurrent Dermatofibrosarcoma Protuberans. *J Cancer* 2017;8:1319-1323. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28607608>.
32. Goldblum JR, Reith JD, Weiss SW. Sarcomas arising in dermatofibrosarcoma protuberans: a reappraisal of biologic behavior in eighteen cases treated by wide local excision with extended clinical follow up. *Am J Surg Pathol* 2000;24:1125-1130. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10935653>.
33. Castle KO, Guadagnolo BA, Tsai CJ, et al. Dermatofibrosarcoma protuberans: long-term outcomes of 53 patients treated with conservative surgery and radiation therapy. *Int J Radiat Oncol Biol Phys* 2013;86:585-590. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23628134>.
34. Liang CA, Jambusaria-Pahlajani A, Karia PS, et al. A systematic review of outcome data for dermatofibrosarcoma protuberans with and without fibrosarcomatous change. *J Am Acad Dermatol* 2014;71:781-786. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24755121>.
35. Buck DW, 2nd, Kim JY, Alam M, et al. Multidisciplinary approach to the management of dermatofibrosarcoma protuberans. *J Am Acad Dermatol* 2012;67:861-866. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22387033>.
36. Chappell AG, Doe SC, Worley B, et al. Multidisciplinary surgical treatment approach for dermatofibrosarcoma protuberans: an update. *Arch Dermatol Res* 2021;313:367-372. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32770258>.
37. Zhou X, Sun D, Liu Y, et al. Dermatofibrosarcoma protuberans: our 10-year experience on 80 patients. *J Dermatolog Treat* 2020;31:554-558. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31116621>.
38. Kimmel Z, Ratner D, Kim JY, et al. Peripheral excision margins for dermatofibrosarcoma protuberans: a meta-analysis of spatial data. *Ann Surg Oncol* 2007;14:2113-2120. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17468914>.
39. Chen Y, Jiang G. Association between surgical excision margins and outcomes in patients with dermatofibrosarcoma protuberans: A meta-analysis. *Dermatol Ther* 2021;34:e14954. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33835635>.
40. Gloster HM, Jr., Harris KR, Roenigk RK. A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans. *J Am Acad Dermatol* 1996;35:82-87. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8682970>.
41. DuBay D, Cimmino V, Lowe L, et al. Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. *Cancer* 2004;100:1008-1016. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14983497>.
42. Meguerditchian AN, Wang J, Lema B, et al. Wide excision or Mohs micrographic surgery for the treatment of primary dermatofibrosarcoma protuberans. *Am J Clin Oncol* 2010;33:300-303. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19858696>.
43. Foroozan M, Sei JF, Amini M, et al. Efficacy of Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: systematic review. *Arch Dermatol* 2012;148:1055-1063. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22986859>.
44. Bogucki B, Neuhaus I, Hurst EA. Dermatofibrosarcoma protuberans: a review of the literature. *Dermatol Surg* 2012;38:537-551. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22288484>.
45. Paradisi A, Abeni D, Ruscioni A, et al. Dermatofibrosarcoma protuberans: wide local excision vs. Mohs micrographic surgery. *Cancer Treat Rev* 2008;34:728-736. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18684568>.



NCCN Guidelines Version 1.2024

Dermatofibrosarcoma Protuberans

46. Lowe GC, Onajin O, Baum CL, et al. A Comparison of Mohs Micrographic Surgery and Wide Local Excision for Treatment of Dermatofibrosarcoma Protuberans With Long-Term Follow-up: The Mayo Clinic Experience. *Dermatol Surg* 2017;43:98-106. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27749444>.
47. Veronese F, Boggio P, Tiberio R, et al. Wide local excision vs. Mohs Tubingen technique in the treatment of dermatofibrosarcoma protuberans: a two-centre retrospective study and literature review. *J Eur Acad Dermatol Venereol* 2017;31:2069-2076. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28573714>.
48. Malan M, Xuejingzi W, Quan SJ. The efficacy of Mohs micrographic surgery over the traditional wide local excision surgery in the cure of dermatofibrosarcoma protuberans. *Pan Afr Med J* 2019;33:297. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31692830>.
49. Durack A, Gran S, Gardiner MD, et al. A 10-year review of surgical management of dermatofibrosarcoma protuberans. *Br J Dermatol* 2021;184:731-739. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32599647>.
50. Nieto-Benito LM, Ciudad-Blanco C, Sanmartin-Jimenez O, et al. Mohs micrographic surgery in dermatofibrosarcoma protuberans: Rate and risk factors for recurrence in a prospective cohort study from the Spanish Registry of Mohs Surgery (REGESMOHS) and review of the literature. *Exp Dermatol* 2021;30:717-722. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33523531>.
51. Asilian A, Honarjou N, Faghihi G, et al. An experience of slow-Mohs micrographic surgery for the treatment of Dermatofibrosarcoma protuberans: A long-term cohort study. *J Cosmet Dermatol* 2020;19:2701-2705. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32039548>.
52. Cammarata E, Esposto E, Veronese F, et al. Safety margins for dermatofibrosarcoma protuberans: a comparison between wide local excision and Mohs Tubingen technique. *Eur J Dermatol* 2020;30:289-293. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32576543>.
53. Lee SH, Oh Y, Nam KA, et al. Mohs micrographic surgery for dermatofibrosarcoma protuberans: comparison of frozen and paraffin techniques. *J Eur Acad Dermatol Venereol* 2018;32:2171-2177. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30067886>.
54. Farma JM, Ammori JB, Zager JS, et al. Dermatofibrosarcoma protuberans: how wide should we resect? *Ann Surg Oncol* 2010;17:2112-2118. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20354798>.
55. Snow H, Davies E, Strauss DC, et al. Conservative Re-excision is a Safe and Simple Alternative to Radical Resection in Revision Surgery for Dermatofibrosarcoma Protuberans. *Ann Surg Oncol* 2020;27:919-923. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31664620>.
56. Harati K, Lange K, Goertz O, et al. A single-institutional review of 68 patients with dermatofibrosarcoma protuberans: wide re-excision after inadequate previous surgery results in a high rate of local control. *World J Surg Oncol* 2017;15:5. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28056985>.
57. Suit H, Spiro I, Mankin HJ, et al. Radiation in management of patients with dermatofibrosarcoma protuberans. *J Clin Oncol* 1996;14:2365-2369. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8708729>.
58. Uysal B, Sager O, Gamsiz H, et al. Evaluation of the role of radiotherapy in the management of dermatofibrosarcoma protuberans. *J BUON* 2013;18:268-273. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23613415>.
59. Hamid R, Hafeez A, Darzi MA, et al. Outcome of wide local excision in dermatofibrosarcoma protuberans and use of radiotherapy for margin-positive disease. *Indian Dermatol Online J* 2013;4:93-96. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23741663>.



60. Ballo MT, Zagars GK, Pisters P, Pollack A. The role of radiation therapy in the management of dermatofibrosarcoma protuberans. *Int J Radiat Oncol Biol Phys* 1998;40:823-827. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9531366>.
61. Dagan R, Morris CG, Zlotecki RA, et al. Radiotherapy in the treatment of dermatofibrosarcoma protuberans. *Am J Clin Oncol* 2005;28:537-539. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16317260>.
62. Sun LM, Wang CJ, Huang CC, et al. Dermatofibrosarcoma protuberans: treatment results of 35 cases. *Radiother Oncol* 2000;57:175-181. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11054521>.
63. Williams N, Morris CG, Kirwan JM, et al. Radiotherapy for dermatofibrosarcoma protuberans. *Am J Clin Oncol* 2014;37:430-432. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23388563>.
64. Haas RL, Keus RB, Loftus BM, et al. The role of radiotherapy in the local management of dermatofibrosarcoma protuberans. *Soft Tissue Tumours Working Group. Eur J Cancer* 1997;33:1055-1060. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/9376187>.
65. Chen YT, Tu WT, Lee WR, Huang YC. The efficacy of adjuvant radiotherapy in dermatofibrosarcoma protuberans: a systemic review and meta-analysis. *J Eur Acad Dermatol Venereol* 2016;30:1107-1114. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26879523>.
66. Takahira T, Oda Y, Tamiya S, et al. Detection of COL1A1-PDGFB fusion transcripts and PDGFB/PDGFRB mRNA expression in dermatofibrosarcoma protuberans. *Mod Pathol* 2007;20:668-675. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17431412>.
67. Patel KU, Szabo SS, Hernandez VS, et al. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. *Hum Pathol* 2008;39:184-193. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17950782>.
68. Simon MP, Pedeutour F, Sirvent N, et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. *Nat Genet* 1997;15:95-98. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8988177>.
69. Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. *J Clin Oncol* 2010;28:1772-1779. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20194851>.
70. Navarrete-Dechent C, Mori S, Barker CA, et al. Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans: A Systematic Review. *JAMA Dermatol* 2019;155:361-369. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30601909>.
71. Ugurel S, Mentzel T, Utikal J, et al. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up. *Clin Cancer Res* 2014;20:499-510. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24173542>.
72. Kerob D, Porcher R, Verola O, et al. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. *Clin Cancer Res* 2010;16:3288-3295. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20439456>.
73. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and Clinical Analysis of Locally Advanced Dermatofibrosarcoma Protuberans Treated With Imatinib: Imatinib Target Exploration Consortium Study B2225. *J Clin Oncol* 2005;23:866-873. Available at: <http://www.jco.org/cgi/content/abstract/23/4/866>.
74. Rutkowski P, Debiec-Rychter M, Nowecki Z, et al. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection. *J Eur Acad Dermatol Venereol*



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 1.2024 Dermatofibrosarcoma Protuberans

2011;25:264-270. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/20569296>.

